Skip to main content

Table 1 Demographic and baseline characteristics (safety population)

From: Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease

Characteristics

N = 33

Race, n (%)

 

  Caucasian

32 (97%)

  Hispanic or Latino

1 (3%)

Gender, n (%)

 

  Male

19 (58%)

Age, years

 

  Mean (SD)

59.0 (6.7)

  Median (Range)

58.1 (44–71)

Smoking Status, n (%)

 

  Current Smoker

18 (55%)

Years Ago Quit, n

15

  Mean (SD)

10.2 (7.7)

  Median (Range)

9.5 (0–27)

Number of Years Smoked

 

  Mean (SD)

38.6 (10.5)

  Median (Range)

40.0 (13–57)

FEV1, L/sec, prebronchodilator

 

  Mean (SD)

1.6 (0.5)

  Median (Range)

1.5 (0.9–3.0)

FEV1, % predicted, prebronchodilator

 

  Mean (SD)

50.5 (9.9)

  Median (Range)

47.3 (35.5–69.3)

FEV1, % predicted, postbronchodilator

 

  Mean (SD)

60.6 (10.3)

  Median (Range)

57.6 (43.0–80.5)

  1. FEV1 = forced expiratory volume in 1 second; SD = standard deviation; L=liter